Takahiro Ozutsumi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5716603/publications.pdf

Version: 2024-02-01

22 papers 207 citations

1040056 9 h-index 1125743 13 g-index

24 all docs

24 docs citations

times ranked

24

214 citing authors

#	Article	IF	CITATIONS
1	Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study. Clinical Endoscopy, 2022, 55, 434-442.	1.5	4
2	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis. Indian Journal of Gastroenterology, 2022, 41, 169-180.	1.4	5
3	Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. International Journal of Molecular Sciences, 2021, 22, 6921.	4.1	16
4	Small intestinal follicular lymphoma induced by methotrexate: a case report. BMC Gastroenterology, 2021, 21, 280.	2.0	2
5	Clinical Significance of Gamma-Glutamyltranspeptidase Combined with Carbohydrate-Deficient Transferrin for the Assessment of Excessive Alcohol Consumption in Patients with Alcoholic Cirrhosis. Medicines (Basel, Switzerland), 2021, 8, 39.	1.4	4
6	The association between sarcopenia and endotoxin in patients with alcoholic cirrhosis. Medicine (United States), 2021, 100, e27212.	1.0	10
7	Comparison of the efficacy and safety between palliative biliary stent placement and duct clearance among elderly patients with choledocholithiasis: a propensity score-matched analysis. BMC Gastroenterology, 2021, 21, 369.	2.0	2
8	The Combination of Albumin–Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child–Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria. Journal of Clinical Medicine, 2021, 10, 4838.	2.4	4
9	Association between Equol Production Status and Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences, 2021, 22, 11904.	4.1	6
10	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences, 2020, 21, 5589.	4.1	21
11	Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. Journal of Clinical Medicine, 2020, 9, 1635.	2.4	11
12	Isolated Pancreatic Sarcoidosis Diagnosed by Endoscopic Ultrasound-guided Fine-needle Aspiration. Internal Medicine, 2020, 59, 1407-1412.	0.7	0
13	Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. Microorganisms, 2020, 8, 925.	3.6	18
14	Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males. Nutrients, 2020, 12, 1036.	4.1	9
15	Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. Antibiotics, 2020, 9, 145.	3.7	33
16	Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. International Journal of Molecular Sciences, 2020, 21, 2164.	4.1	12
17	TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. Cells, 2019, 8, 1153.	4.1	16
18	Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidaseâ€4 inhibitor on hepatic fibrosis. Hepatology Research, 2019, 49, 1147-1161.	3.4	9

#	Article	IF	CITATIONS
19	Identification of clinical risk factors for histological progression of primary biliary cholangitis. Hepatology Research, 2019, 49, 1015-1025.	3.4	9
20	Calcified mucinous adenocarcinoma of the stomach metastatic to the iris: a case report. Journal of Medical Case Reports, 2019, 13, 64.	0.8	3
21	Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. Hepatology Research, 2019, 49, 232-238.	3.4	9
22	Efficacy and tolerability of interferon‑free regimen for patients with genotype‑1 HCV infection. Experimental and Therapeutic Medicine, 2018, 16, 2743-2750.	1.8	4